{
    "clinical_study": {
        "@rank": "89097", 
        "arm_group": [
            {
                "arm_group_label": "Nintedanib", 
                "arm_group_type": "Experimental", 
                "description": "150 mg twice daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "twice daily dosing"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an 12 month multi-centre, prospective, randomized, placebo controlled, double blind\n      clinical trial designed to assess the effect of nintedanib 150mg BID on the progression of\n      IPF measured by using  HRCT, lung function, 6MWT, biomarkers, and PROs with  continued\n      treatment and assessments for up to 18 months."
        }, 
        "brief_title": "Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Idiopathic Pulmonary Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Pulmonary Fibrosis", 
                "Idiopathic Pulmonary Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Written Informed Consent consistent with International Conference on\n             Harmonisation-Good  Clinical Practice and local laws signed prior to entry into the\n             study\n\n          2. Patient aged = 40 years at visit 1\n\n          3. IPF diagnosed, according to the 2011 American Thoracic Society (ATS)/European\n             Respiratory Society (ERS) /Japanese Respiratory Society (JRS)/Latin American Thoracic\n             Society (ALAT) IPF guidelines for diagnosis Usual Interstitial Pneumonia (UIP)\n             management, within 5 years of Visit 0. All HRCT found to be possible UIP must have\n             confirmatory pathology\n\n          4. Carbon Monoxide Diffusing Capacity (DLCO) (corrected for Hb): 30%-79% predicted of\n             normal\n\n          5. Full Vital Capacity (FVC) predicted of normal\n\n        Exclusion criteria:\n\n          1. Aspartate Amino Transferase (AST), Alanine Amino Transferase (ALT) > 1.5 fold Upper\n             Limit Normal (ULN)\n\n          2. Bilirubin > 1.5 fold ULN\n\n          3. Bleeding risk:\n\n               1. Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g.\n                  vitamin K antagonists, dabigatran, heparin, hirudin), or high dose antiplatelet\n                  therapy. Exceptions: prophylactic low dose heparin or heparin flush as needed\n                  for maintenance of an indwelling intravenous device (e.g. enoxaparin 4000 IU\n                  s.c. per day) and prophylactic use of antiplatelet therapy (e.g. acetyl\n                  salicylic acid up to 325 mg/d, or clopidogrel at 75 mg/d, or equivalent doses of\n                  other antiplatelet therapy)\n\n               2. History of hemorrhagic Central Nervous System (CNS) event within 12 months\n\n               3. Any of the following within 3 months:  Haemoptysis or haematuria, active\n                  gastro-intestinal bleeding or ulcers, major injury or surgery\n\n               4. Coagulation parameters: International normalised ratio (INR) > 2, prothrombin\n                  time (PT) and partial thromboplastin time (PTT) > 150% of institutional ULN\n\n          4. Planned major surgery within the next 3 months, including lung transplantation, major\n             abdominal or major intestinal surgery\n\n          5. Thrombotic risk:\n\n               1. Known inherited predisposition to thrombosis\n\n               2. History of thrombotic event (including stroke and transient ischemic attacks)\n                  within 12 months\n\n          6. Current or planned usage of any investigational drug during the course of this trial\n\n          7. Previous treatment with nintedanib within a clinical trial in the previous 3 months\n             and discontinuation of nintedanib study treatment due to an adverse event\n\n          8. Known hypersensitivity to the trial drug or its component\n\n          9. A disease or condition which in the opinion of investigator may put the patient at\n             risk because of participation in this trial or limit the patient\u00bfs ability to\n             participate in this trial\n\n         10. Alcohol or drug abuse which in the opinion of the investigator would interfere with\n             trial participation\n\n         11. Pregnant women or women who are breast feeding or of child bearing potential not\n             using two effective methods of birth control (one barrier and one highly effective\n             non-barrier) for at least 1 month prior to trial and/or not committing to using it\n             until 3 months after end of treatment\n\n         12. Women will be considered to be of childbearing potential unless surgically sterilised\n             by hysterectomy or bilateral tubal ligation, or postmenopausal for at least two\n             years;  Highly effective methods of birth control include established use of oral,\n             injected or implanted hormonal methods of contraception, placement of an intrauterine\n             device (IUD) or intrauterine system (IUS). A barrier method of contraception includes\n             condom or occlusive cap with spermicidal (foam, gel, film, cream, suppository) or\n             male sterilization (with appropriate post vasectomy documentation of the absence of\n             sperm in the ejaculate)\n\n         13. Sexually active males not committing to using condoms during the course of the study\n             (except if their partner is not of childbearing potential) and 3 months after end of\n             treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "275", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01979952", 
            "org_study_id": "1199.187"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "twice daily dosing", 
                "intervention_name": "Matching Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Nintedanib", 
                "description": "gelating capsule", 
                "intervention_name": "Nintedanib", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "1199.187.01044 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1199.187.01006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1199.187.01039 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Danbury", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }, 
                    "name": "1199.187.01007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1199.187.01045 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1199.187.01009 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winter Park", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1199.187.01047 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Skokie", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "1199.187.01015 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }, 
                    "name": "1199.187.01033 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fridley", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "1199.187.01013 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "1199.187.01002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire"
                    }, 
                    "name": "1199.187.01008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cedar Knolls", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "1199.187.01036 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mineola", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "1199.187.01011 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "1199.187.01043 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "1199.187.01041 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "1199.187.01004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "1199.187.01014 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "1199.187.01012 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "1199.187.01042 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "1199.187.01046 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "1199.187.01001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1199.187.01016 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta"
                    }, 
                    "name": "1199.187.02004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "1199.187.02005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "1199.187.02007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba"
                    }, 
                    "name": "1199.187.02001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia"
                    }, 
                    "name": "1199.187.02003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "1199.187.02002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherbrooke", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "1199.187.02008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double Blind Randomized Placebo Controlled Trial Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Twelve Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Relative change from baseline in HRCT Quantitative Lung Fibrosis (QLF) score", 
            "safety_issue": "No", 
            "time_frame": "at 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01979952"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "FVC absolute and relative change from baseline", 
                "safety_issue": "No", 
                "time_frame": "at 12 month"
            }, 
            {
                "measure": "St. George's Respiratory Questionnaire (SGRQ) total score change from baseline", 
                "safety_issue": "No", 
                "time_frame": "at 12 months"
            }, 
            {
                "measure": "6MWT total distance walked change from baseline", 
                "safety_issue": "No", 
                "time_frame": "at 12 months"
            }, 
            {
                "measure": "FVC categorical change from baseline", 
                "safety_issue": "No", 
                "time_frame": "at 12 months"
            }, 
            {
                "measure": "University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) change from baseline", 
                "safety_issue": "No", 
                "time_frame": "up to 18 months"
            }, 
            {
                "measure": "Occurrence of all cause mortality at the end of treatment period", 
                "safety_issue": "No", 
                "time_frame": "up to 18 months"
            }, 
            {
                "measure": "Occurrence of respiratory hospitalizations at the end of treatment period", 
                "safety_issue": "No", 
                "time_frame": "up to 18 months"
            }, 
            {
                "measure": "Occurrence of respiratory mortality at the end of treatment period", 
                "safety_issue": "No", 
                "time_frame": "up to 18 months"
            }, 
            {
                "measure": "Risk ratio of an acute IPF exacerbation at the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "up to 18 months"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}